Evidence of a mild mutator phenotype in cambodian Plasmodium falciparum malaria parasites

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Lee, Andrew H ^a   Fidock, David A ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISIN; CIPARGAMIN; EXONUCLEASE; EXONUCLEASE 1; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; PROTEIN MLH1; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ANTIMALARIAL AGENT; ARTEMISININ; ARTEMISININ DERIVATIVE; INDOLE DERIVATIVE; MUTL PROTEIN HOMOLOG 1; PROTOZOAL PROTEIN; SPIRO COMPOUND;

ANTIBIOTIC RESISTANCE; ARTICLE; CAMBODIA; CONTROLLED STUDY; DNA REPAIR; EUKARYOTE EVOLUTION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALARIA FALCIPARUM; MULTIDRUG RESISTANCE; MUTATION RATE; NONHUMAN; PARASITE ISOLATION; PHENOTYPE; PLASMODIUM FALCIPARUM; ALLELE; DRUG EFFECTS; GENE FREQUENCY; GENETICS; MALARIA, FALCIPARUM; MUTATION; PARASITOLOGY;

ALLELES; ANTIMALARIALS; ARTEMISININS; CAMBODIA; DRUG RESISTANCE, MULTIPLE; GENE FREQUENCY; HUMANS; INDOLES; MALARIA, FALCIPARUM; MUTATION; MUTL PROTEIN HOMOLOG 1; PHENOTYPE; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; SODIUM-POTASSIUM-EXCHANGING ATPASE; SPIRO COMPOUNDS;

EID: 84964665932     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0154166     Document Type: Article

References (58)

1. WHO. Global plan for insecticide resistance management in malaria vectors. 2012.
2. Dondorp AM, Fairhurst RM, Slutsker L, Macarthur JR, Breman JG, Guerin PJ, et al. The threat of artemisinin- resistant malaria. N Engl J Med. 2011; 365(12):1073-5. doi: 10.1056/NEJMp1108322 PMID: 21992120.
3. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014; 371(5):411-23. doi: 10.1056/NEJMoa1314981 PMID: 25075834.
4. Sa JM, Chong JL, Wellems TE. Malaria drug resistance: new observations and developments. Essays Biochem. 2011; 51:137-60. doi: 10.1042/bse0510137 PMID: 22023447.
5. Takala-Harrison S, Laufer MK. Antimalarial drug resistance in Africa: key lessons for the future. Ann N Y Acad Sci. 2015; 1342:62-7. doi: 10.1111/nyas.12766 PMID: 25891142.
6. Vinayak S, Alam MT, Mixson-Hayden T, McCollum AM, Sem R, Shah NK, et al. Origin and evolution of sulfadoxine resistant Plasmodium falciparum. PLoS Pathog. 2010; 6(3):e1000830. doi: 10.1371/journal.ppat.1000830 PMID: 20360965.
7. Venkatesan M, Alifrangis M, Roper C, Plowe CV. Monitoring antifolate resistance in intermittent preventive therapy for malaria. Trends Parasitol. 2013; 29(10):497-504. doi: 10.1016/j.pt.2013.07.008 PMID: 23948432.
8. Rathod PK, McErlean T, Lee PC. Variations in frequencies of drug resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A. 1997; 94(17):9389-93. PMID: 9256492.
9. Miotto O, Almagro-Garcia J, Manske M, Macinnis B, Campino S, Rockett KA, et al. Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat Genet. 2013; 45(6):648-55. doi: 10. 1038/ng.2624 PMID: 23624527.
10. Bopp SE, Manary MJ, Bright AT, Johnston GL, Dharia NV, Luna FL, et al. Mitotic evolution of Plasmodium falciparum shows a stable core genome but recombination in antigen families. PLoS Genet. 2013; 9(2):e1003293. doi: 10.1371/journal.pgen.1003293 PMID: 23408914.
11. Claessens A, Hamilton WL, Kekre M, Otto TD, Faizullabhoy A, Rayner JC, et al. Generation of antigenic diversity in Plasmodium falciparum by structured rearrangement of Var genes during mitosis. PLoS Genet. 2014; 10(12):e1004812. doi: 10.1371/journal.pgen.1004812 PMID: 25521112.
12. Brown TS, Jacob CG, Silva JC, Takala-Harrison S, Djimde A, Dondorp AM, et al. Plasmodium falciparum field isolates from areas of repeated emergence of drug resistant malaria show no evidence of hypermutator phenotype. Infect Genet Evol. 2015; 30:318-22. doi: 10.1016/j.meegid.2014.12.010 PMID: 25514047.
13. Baquero MR, Nilsson AI, Turrientes Mdel C, Sandvang D, Galan JC, Martinez JL, et al. Polymorphic mutation frequencies in Escherichia coli: emergence of weak mutators in clinical isolates. J Bacteriol. 2004; 186(16):5538-42. doi: 10.1128/JB.186.16.5538-5542.2004 PMID: 15292159.
14. Denamur E, Tenaillon O, Deschamps C, Skurnik D, Ronco E, Gaillard JL, et al. Intermediate mutation frequencies favor evolution of multidrug resistance in Escherichia coli. Genetics. 2005; 171(2):825-7. doi: 10.1534/genetics.105.045526 PMID: 15965238.
15. Gustafsson I, Sjolund M, Torell E, Johannesson M, Engstrand L, Cars O, et al. Bacteria with increased mutation frequency and antibiotic resistance are enriched in the commensal flora of patients with high antibiotic usage. J Antimicrob Chemother. 2003; 52(4):645-50. doi: 10.1093/jac/dkg427 PMID: 12972454.
16. Orlen H, Hughes D. Weak mutators can drive the evolution of fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother. 2006; 50(10):3454-6. doi: 10.1128/AAC.00783-06 PMID: 17005830.
17. Barrick JE, Lenski RE. Genome dynamics during experimental evolution. Nat Rev Genet. 2013; 14(12): 827-39. doi: 10.1038/nrg3564 PMID: 24166031.
18. Denamur E, Matic I. Evolution of mutation rates in bacteria. Mol Microbiol. 2006; 60(4):820-7. doi: 10. 1111/j.1365-2958.2006.05150.x PMID: 16677295.
19. Rottmann M, McNamara C, Yeung BK, Lee MC, Zou B, Russell B, et al. Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010; 329(5996):1175-80. doi: 10.1126/science. 1193225 PMID: 20813948.
20. Amaratunga C, Sreng S, Suon S, Phelps ES, Stepniewska K, Lim P, et al. Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis. 2012; 12(11):851-8. doi: 10.1016/S1473-3099(12)70181-0 PMID: 22940027.
21. Straimer J, Gnadig NF, Witkowski B, Amaratunga C, Duru V, Ramadani AP, et al. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science. 2015; 347(6220):428-31. doi: 10.1126/science.1260867 PMID: 25502314.
22. Fidock DA, Nomura T, Wellems TE. Cycloguanil and its parent compound proguanil demonstrate distinct activities against Plasmodium falciparum malaria parasites transformed with human dihydrofolate reductase. Mol Pharmacol. 1998; 54(6):1140-7. PMID: 9855645.
23. Sidhu AB, Valderramos SG, Fidock DA. pfmdr1 mutations contribute to quinine resistance and enhance mefloquine and artemisinin sensitivity in Plasmodium falciparum. Mol Microbiol. 2005; 57(4): 913-26. doi: 10.1111/j.1365-2958.2005.04729.x PMID: 16091034.
24. Goodyer ID, Taraschi TF. Plasmodium falciparum: a simple, rapid method for detecting parasite clones in microtiter plates. Exp Parasitol. 1997; 86(2):158-60. doi: 10.1006/expr.1997.4156 PMID: 9207746.
25. Ekland EH, Schneider J, Fidock DA. Identifying apicoplast-targeting antimalarials using highthroughput compatible approaches. FASEB J. 2011; 25(10):3583-93. doi: 10.1096/fj.11-187401 PMID: 21746861.
26. Hall BM, Ma CX, Liang P, Singh KK. Fluctuation analysis CalculatOR: a web tool for the determination of mutation rate using Luria-Delbruck fluctuation analysis. Bioinformatics. 2009; 25(12):1564-5. doi: 10.1093/bioinformatics/btp253 PMID: 19369502.
27. Foster PL. Methods for determining spontaneous mutation rates. Methods Enzymol. 2006; 409: 195-213. doi: 10.1016/S0076-6879(05)09012-9 PMID: 16793403.
28. Greene CN, Jinks-Robertson S. Spontaneous frameshift mutations in Saccharomyces cerevisiae: accumulation during DNA replication and removal by proofreading and mismatch repair activities. Genetics. 2001; 159(1):65-75. PMID: 11560887.
29. Demogines A, Wong A, Aquadro C, Alani E. Incompatibilities involving yeast mismatch repair genes: a role for genetic modifiers and implications for disease penetrance and variation in genomic mutation rates. PLoS Genet. 2008; 4(6):e1000103. doi: 10.1371/journal.pgen.1000103 PMID: 18566663.
30. Amin NS, Nguyen MN, Oh S, Kolodner RD. exo1-dependent mutator mutations: model system for studying functional interactions in mismatch repair. Mol Cell Biol. 2001; 21(15):5142-55. doi: 10.1128/MCB.21.15.5142-5155.2001 PMID: 11438669.
31. Luria SE, Delbruck M. Mutations of bacteria from virus sensitivity to virus resistance. Genetics. 1943; 28(6):491-511. PMID: 17247100.
32. Rosche WA, Foster PL. Determining mutation rates in bacterial populations. Methods. 2000; 20(1): 4-17. doi: 10.1006/meth.1999.0901 PMID: 10610800.
33. Diagana TT. Supporting malaria elimination with 21st century antimalarial agent drug discovery. Drug Discov Today. 2015; 20(10):1265-70. doi: 10.1016/j.drudis.2015.06.009 PMID: 26103616.
34. Spillman NJ, Allen RJ, McNamara CW, Yeung BK, Winzeler EA, Diagana TT, et al. Na(+) regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials. Cell Host Microbe. 2013; 13(2):227-37. doi: 10.1016/j.chom.2012.12.006 PMID: 23414762.
35. Jimenez-Diaz MB, Ebert D, Salinas Y, Pradhan A, Lehane AM, Myrand-Lapierre ME, et al. (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium. Proc Natl Acad Sci U S A. 2014; 111(50):E5455-62. doi: 10.1073/pnas.1414221111 PMID: 25453091.
36. Lehane AM, Ridgway MC, Baker E, Kirk K. Diverse chemotypes disrupt ion homeostasis in the malaria parasite. Mol Microbiol. 2014; 94(2):327-39. doi: 10.1111/mmi.12765 PMID: 25145582.
37. White NJ, Pukrittayakamee S, Phyo AP, Rueangweerayut R, Nosten F, Jittamala P, et al. Spiroindolone KAE609 for falciparum and vivax malaria. N Engl J Med. 2014; 371(5):403-10. doi: 10.1056/NEJMoa1315860 PMID: 25075833.
38. Wei K, Clark AB, Wong E, Kane MF, Mazur DJ, Parris T, et al. Inactivation of Exonuclease 1 in mice results in DNA mismatch repair defects, increased cancer susceptibility, and male and female sterility. Genes Dev. 2003; 17(5):603-14. doi: 10.1101/gad.1060603 PMID: 12629043.
39. Udeinya IJ, Graves PM, Carter R, Aikawa M, Miller LH. Plasmodium falciparum: effect of time in continuous culture on binding to human endothelial cells and amelanotic melanoma cells. Exp Parasitol. 1983; 56(2):207-14. PMID: 6352321.
40. Yuthavong Y, Tarnchompoo B, Vilaivan T, Chitnumsub P, Kamchonwongpaisan S, Charman SA, et al. Malarial dihydrofolate reductase as a paradigm for drug development against a resistance- compromised target. Proc Natl Acad Sci U S A. 2012; 109(42):16823-8. doi: 10.1073/pnas.1204556109 PMID: 23035243.
41. Oduola AM, Milhous WK, Weatherly NF, Bowdre JH, Desjardins RE. Plasmodium falciparum: induction of resistance to mefloquine in cloned strains by continuous drug exposure in vitro. Exp Parasitol. 1988; 67(2):354-60. PMID: 3056740.
42. Gabryszewski SJ, Modchang C, Musset L, Chookajorn T, Fidock DA. Combinatorial genetic modeling of pfcrt-mediated drug resistance evolution in Plasmodium falciparum. Mol Biol Evol. 2016;(in press).
43. Srivastava IK, Morrisey JM, Darrouzet E, Daldal F, Vaidya AB. Resistance mutations reveal the atovaquone- binding domain of cytochrome b in malaria parasites. Mol Microbiol. 1999; 33(4):704-11. PMID: 10447880.
44. Sokolsky T, Alani E. EXO1 and MSH6 are high-copy suppressors of conditional mutations in the MSH2 mismatch repair gene of Saccharomyces cerevisiae. Genetics. 2000; 155(2):589-99. PMID: 10835383.
45. Flannery EL, McNamara CW, Kim SW, Kato TS, Li F, Teng CH, et al. Mutations in the P-type cationtransporter ATPase 4, PfATP4, mediate resistance to both aminopyrazole and spiroindolone antimalarials. ACS Chem Biol. 2015; 10(2):413-20. doi: 10.1021/cb500616x PMID: 25322084.
46. Vaidya AB, Morrisey JM, Zhang Z, Das S, Daly TM, Otto TD, et al. Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum. Nat Commun. 2014; 5:5521. doi: 10.1038/ncomms6521 PMID: 25422853.
47. Leong FJ, Li R, Jain JP, Lefevre G, Magnusson B, Diagana TT, et al. A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial Spiroindolone KAE609 (Cipargamin) to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers. Antimicrob Agents Chemother. 2014; 58(10):6209-14. doi: 10.1128/AAC.03393-14 PMID: 25114127.
48. Gueneau E, Dherin C, Legrand P, Tellier-Lebegue C, Gilquin B, Bonnesoeur P, et al. Structure of the MutLalpha C-terminal domain reveals how Mlh1 contributes to Pms1 endonuclease site. Nat Struct Mol Biol. 2013; 20(4):461-8. doi: 10.1038/nsmb.2511 PMID: 23435383.
49. Boiteux S, Jinks-Robertson S. DNA repair mechanisms and the bypass of DNA damage in Saccharomyces cerevisiae. Genetics. 2013; 193(4):1025-64. doi: 10.1534/genetics.112.145219 PMID: 23547164.
50. Takahashi M, Shimodaira H, Andreutti-Zaugg C, Iggo R, Kolodner RD, Ishioka C. Functional analysis of human MLH1 variants using yeast and in vitro mismatch repair assays. Cancer Res. 2007; 67(10): 4595-604. doi: 10.1158/0008-5472.CAN-06-3509 PMID: 17510385.
51. Malaria GENPfCP. Genomic epidemiology of artemisinin resistant malaria. Elife. 2016; 5. doi: 10.7554/eLife.08714 PMID: 26943619.
52. Tran PT, Liskay RM. Functional studies on the candidate ATPase domains of Saccharomyces cerevisiae MutLalpha. Mol Cell Biol. 2000; 20(17):6390-8. PMID: 10938116.
53. Zakharyevich K, Tang S, Ma Y, Hunter N. Delineation of joint molecule resolution pathways in meiosis identifies a crossover-specific resolvase. Cell. 2012; 149(2):334-47. doi: 10.1016/j.cell.2012.03.023 PMID: 22500800.
54. Wang TF, Kleckner N, Hunter N. Functional specificity of MutL homologs in yeast: evidence for three Mlh1-based heterocomplexes with distinct roles during meiosis in recombination and mismatch correction. Proc Natl Acad Sci U S A. 1999; 96(24):13914-9. PMID: 10570173.
55. Miotto O, Amato R, Ashley EA, MacInnis B, Almagro-Garcia J, Amaratunga C, et al. Genetic architecture of artemisinin-resistant Plasmodium falciparum. Nat Genet. 2015; 47(3):226-34. doi: 10.1038/ng. 3189 PMID: 25599401.
56. Finn RD, Bateman A, Clements J, Coggill P, Eberhardt RY, Eddy SR, et al. Pfam: the protein families database. Nucleic Acids Res. 2014; 42(Database issue):D222-30. doi: 10.1093/nar/gkt1223 PMID: 24288371.
57. Yang J, Zhang Y. I-TASSER server: new development for protein structure and function predictions. Nucleic Acids Res. 2015; 43(W1):W174-81. doi: 10.1093/nar/gkv342 PMID: 25883148.
58. Spillman NJ, Kirk K. The malaria parasite cation ATPase PfATP4 and its role in the mechanism of action of a new arsenal of antimalarial drugs. Int J Parasitol Drugs Drug Resist. 2015; 5(3):149-62. doi: 10.1016/j.ijpddr.2015.07.001 PMID: 26401486.